Cardiff Oncology, Inc. (CRDF)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 90K 180K 270K Q3 '16: 89.1K Q4 '16: 68K Q1 '17: 95K Q2 '17: 102K Q3 '17: 123.3K Q4 '17: 185K Q1 '18: 100.1K Q2 '18: 111.8K Q3 '18: 88.4K Q4 '18: 78K Q1 '19: 62K Q2 '19: 36.9K Q3 '19: 51.7K Q4 '19: 92.6K Q1 '20: 68K Q2 '20: 43K Q3 '20: 136K Q4 '20: 119K Q1 '21: 72K Q2 '21: 68K Q3 '21: 86K Q4 '21: 133K Q1 '22: 74K Q2 '22: 91K Q3 '22: 93K Q4 '22: 128K Q1 '23: 83K Q2 '23: 108K Q3 '23: 141K Q4 '23: 156K Q1 '24: 205K Q2 '24: 163K Q3 '24: 165K Q4 '24: 151K Q1 '25: 109K Q2 '25: 121K Q3 '25: 120K Q4 '25: 243K Q1 '26: 41K Q2 '26: 104K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

-600K -400K -200K 0 200K 400K 600K Q3 '14: 57.2K Q4 '14: 40.6K Q1 '15: -49.5K Q2 '15: -30.7K Q3 '15: -116.2K Q4 '15: -120.2K Q1 '16: -188.8K Q2 '16: -306.1K Q3 '16: -335.4K Q4 '16: -519.2K Q1 '17: -521.4K Q2 '17: -236.2K Q3 '17: -349.9K Q4 '17: -198.6K Q1 '18: -266.2K Q2 '18: -92.6K Q3 '18: 61.7K Q4 '18: 78K Q1 '19: 62K Q2 '19: 36.9K Q3 '19: 51.7K Q4 '19: 92.6K Q3 '14 Q2 '15 Q1 '16 Q4 '16 Q3 '17 Q2 '18 Q1 '19 Q4 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '16: -9.9M Q4 '16: -9.8M Q1 '17: -10.1M Q2 '17: -5.9M Q3 '17: -5.8M Q4 '17: -3.8M Q1 '18: -4.7M Q2 '18: -4.4M Q3 '18: -3.9M Q4 '18: -4.1M Q1 '19: -4M Q2 '19: -4.2M Q3 '19: -4.2M Q4 '19: -4.3M Q1 '20: -4.1M Q2 '20: -4.1M Q3 '20: -4.4M Q4 '20: -6.5M Q1 '21: -5.4M Q2 '21: -6.9M Q3 '21: -7M Q4 '21: -9.5M Q1 '22: -11.1M Q2 '22: -10.4M Q3 '22: -9M Q4 '22: -9.4M Q1 '23: -12.1M Q2 '23: -12.2M Q3 '23: -10.8M Q4 '23: -10.3M Q1 '24: -10.9M Q2 '24: -12.5M Q3 '24: -12.6M Q4 '24: -12.6M Q1 '25: -14.4M Q2 '25: -14.8M Q3 '25: -12M Q4 '25: -7.8M Q1 '26: -12.8M Q2 '26: -9.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '16: -10.2M Q4 '16: -8.5M Q1 '17: -10M Q2 '17: -8M Q3 '17: -4.3M Q4 '17: -2.6M Q1 '18: -4.8M Q2 '18: -3.7M Q3 '18: -3.8M Q4 '18: -4.2M Q1 '19: -3.9M Q2 '19: -4.1M Q3 '19: -4.1M Q4 '19: -4.2M Q1 '20: -4.1M Q2 '20: -4.1M Q3 '20: -4.5M Q4 '20: -6.6M Q1 '21: -5.2M Q2 '21: -6.8M Q3 '21: -6.9M Q4 '21: -9.4M Q1 '22: -11M Q2 '22: -10.4M Q3 '22: -8.6M Q4 '22: -8.7M Q1 '23: -11.2M Q2 '23: -11.2M Q3 '23: -9.7M Q4 '23: -9.3M Q1 '24: -10M Q2 '24: -11.8M Q3 '24: -11.9M Q4 '24: -11.8M Q1 '25: -13.4M Q2 '25: -13.9M Q3 '25: -11.3M Q4 '25: -7.2M Q1 '26: -12.3M Q2 '26: -9.2M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

0 250K 500K 750K Q3 '14: 0 Q4 '14: 15.4K Q1 '15: 176.4K Q2 '15: 80K Q3 '15: 173.5K Q4 '15: 199.2K Q1 '16: 309.3K Q2 '16: 409.5K Q3 '16: 424.6K Q4 '16: 587.2K Q1 '17: 616.4K Q2 '17: 338.2K Q3 '17: 473.2K Q4 '17: 383.6K Q1 '18: 366.3K Q2 '18: 204.4K Q3 '18: 26.7K Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q3 '14 Q2 '15 Q1 '16 Q4 '16 Q3 '17 Q2 '18 Q1 '19 Q4 '19

Operating Cash Flow Quarterly

-15M -10M -5M 0 5M 10M 15M Q3 '16: -7M Q4 '16: -9M Q1 '17: -8.8M Q2 '17: -4.6M Q3 '17: -6.6M Q4 '17: -3.3M Q1 '18: -2.9M Q2 '18: -3.3M Q3 '18: -3.5M Q4 '18: -3.6M Q1 '19: -3.4M Q2 '19: -3.4M Q3 '19: -3.2M Q4 '19: -3.3M Q1 '20: -3.4M Q2 '20: -4.3M Q3 '20: -3.5M Q4 '20: -5.1M Q1 '21: -5.9M Q2 '21: -4.3M Q3 '21: -5.5M Q4 '21: -7.4M Q1 '22: -10.2M Q2 '22: -6.7M Q3 '22: -7.5M Q4 '22: -9.4M Q1 '23: -8.7M Q2 '23: -7.1M Q3 '23: -8M Q4 '23: -7.1M Q1 '24: -7.7M Q2 '24: -9.2M Q3 '24: -10.5M Q4 '24: -10.3M Q1 '25: -12.8M Q2 '25: -8.3M Q3 '25: -10.8M Q4 '25: -6M Q1 '26: -12.3M Q2 '26: -11.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-12M -8M -4M 0 4M 8M 12M Q2 '15: -5.9M Q3 '15: -5.7M Q4 '15: -7.8M Q1 '16: -7.3M Q2 '16: -8.4M Q3 '16: -7.2M Q4 '16: -9M Q1 '17: -8.8M Q2 '17: -4.6M Q3 '17: -6.7M Q1 '18: -2.9M Q2 '18: -3.3M Q3 '18: -3.5M Q4 '18: -3.6M Q1 '19: -3.4M Q2 '19: -3.4M Q3 '19: -3.2M Q4 '19: -3.3M Q1 '20: -3.4M Q2 '20: -4.3M Q3 '20: -3.7M Q4 '20: -5.2M Q1 '21: -5.9M Q2 '21: -4.3M Q3 '21: -5.6M Q4 '21: -7.5M Q1 '22: -10.4M Q2 '22: -7M Q3 '22: -7.9M Q4 '22: -9.5M Q1 '23: -8.7M Q2 '23: -7.4M Q3 '23: -8.3M Q4 '23: -7.1M Q1 '24: -7.8M Q2 '24: -9.2M Q3 '24: -10.5M Q4 '24: -10.3M Q3 '25: -10.9M Q4 '25: -6M Q2 '16 Q3 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '14: 19.2M Q3 '14: 18.9M Q4 '14: 19.1M Q1 '15: 21.8M Q2 '15: 24.6M Q3 '15: 29.1M Q4 '15: 30.2M Q1 '16: 30.1M Q2 '16: 30M Q3 '16: 30.3M Q4 '16: 30.7M Q1 '17: 31M Q2 '17: 2.6M Q3 '17: 3M Q4 '17: 40.2M Q1 '18: 769K Q2 '18: 1.2M Q3 '18: 3.4M Q1 '19: 4.1M Q2 '19: 5.2M Q3 '19: 5.8M Q2 '20: 14.5M Q3 '20: 23.3M Q1 '21: 37.2M Q2 '21: 38.8M Q3 '21: 39.6M Q1 '22: 43.2M Q2 '22: 43.3M Q3 '22: 43.3M Q1 '23: 44.7M Q2 '23: 44.7M Q3 '23: 44.7M Q1 '24: 44.7M Q2 '24: 44.8M Q3 '24: 46.9M Q1 '25: 66.5M Q2 '25: 66.5M Q3 '25: 66.9M Q1 '26: 68.3M Q2 '26: 68.4M Q2 '15 Q3 '16 Q4 '17 Q2 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '16: -1.30 Q4 '16: -1.38 Q1 '17: -1.34 Q2 '17: -4.12 Q3 '17: -5.19 Q4 '17: -4.91 Q1 '18: -10.82 Q2 '18: -12.97 Q3 '18: -12.66 Q4 '18: -8.26 Q1 '19: -3.05 Q2 '19: 1.43 Q3 '19: 1.82 Q4 '19: -2.92 Q1 '20: -2.31 Q2 '20: -2.03 Q3 '20: -1.51 Q4 '20: -1.19 Q1 '21: -0.92 Q2 '21: -0.58 Q3 '21: -0.56 Q4 '21: -0.72 Q1 '22: -0.83 Q2 '22: -0.90 Q3 '22: -0.93 Q4 '22: -0.89 Q1 '23: -0.89 Q2 '23: -0.90 Q3 '23: -0.92 Q4 '23: -0.93 Q1 '24: -0.90 Q2 '24: -0.91 Q3 '24: -0.94 Q4 '24: -0.94 Q1 '25: -0.92 Q2 '25: -0.87 Q3 '25: -0.79 Q4 '25: -0.69 Q1 '26: -0.67 Q2 '26: -0.60 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.